Varilrix Dosage/Direction for Use

Powder and solvent for solution for injection.
0.5 ml of reconstituted vaccine contains one immunising dose.
Posology: The immunisation schedules for Varilrix should be based on official recommendations.
Healthy individuals: Children from the age of 9 months as well as adolescents and adults receive two doses of Varilrix to ensure optimal protection against varicella (see Pharmacology: Pharmacodynamics: Pharmacodynamic effects under Actions). The second dose should generally be given at least 6 weeks after the first dose. Under no circumstances should the interval between the doses be less than 4 weeks.
Post-exposure prophylaxis susceptible individuals exposed to varicella should receive one dose of Varilrix within 72 hours of contact.
Individuals at high risk of severe varicella: The same schedule described for healthy individuals should be applied for individuals at high risk of severe varicella (see Pharmacology: Pharmacodynamics: Pharmacodynamic effects under Actions).
In these individuals, periodic measurement of varicella antibodies after vaccination may be indicated in order to identify those who may benefit from re-vaccination. In individuals at high risk of severe varicella additional doses of vaccine might be required. Under no circumstances should the interval between the doses be less than 4 weeks.
Interchangeability: A single dose of Varilrix may be administered to those who have already received a single dose of another varicella-containing vaccine.
A single dose of Varilrix may be administered followed by a single dose of another varicella-containing vaccine.
Method of administration: Varilrix is to be injected subcutaneously (SC) or intramuscularly (IM) in the deltoid region or in the anterolateral area of the thigh.
Varilrix should be administered subcutaneously in individuals with bleeding disorders (e.g. thrombocytopenia or any coagulation disorder).
For instructions on reconstitution of the medicinal product before administration see Instructions for Use/Handling under Cautions for Usage.